Strain-specific effects of probiotics on depression and anxiety: a meta-analysis.

IF 4.3 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Gut Pathogens Pub Date : 2024-09-08 DOI:10.1186/s13099-024-00634-8

Maryam Rahmannia, Mohadeseh Poudineh, Roya Mirzaei, Mohammad Amin Aalipour, Amir Hashem Shahidi Bonjar, Mehdi Goudarzi, Ali Kheradmand, Hamid Reza Aslani, Majid Sadeghian, Mohammad Javad Nasiri, Leonardo Antonio Sechi

{"title":"Strain-specific effects of probiotics on depression and anxiety: a meta-analysis.","authors":"Maryam Rahmannia, Mohadeseh Poudineh, Roya Mirzaei, Mohammad Amin Aalipour, Amir Hashem Shahidi Bonjar, Mehdi Goudarzi, Ali Kheradmand, Hamid Reza Aslani, Majid Sadeghian, Mohammad Javad Nasiri, Leonardo Antonio Sechi","doi":"10.1186/s13099-024-00634-8","DOIUrl":null,"url":null,"abstract":"Introduction: Depression and anxiety are pervasive mental health disorders with substantial global burdens. Probiotics, live microorganisms known for their health benefits, have emerged as a potential therapeutic intervention for these conditions. This systematic review and meta-analysis aim to evaluate the strain-specific effects of probiotics on relieving depressive and anxiety symptoms while elucidating underlying mechanisms.Methods: EMBASE, Cochrane CENTRAL and PubMed/Medline were systematically queried to identify studies released until May 15, 2024. Randomized Controlled Trials (RCTs) that employed standardized assessment tools for depression and anxiety namely Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HAMD), Depression Anxiety Stress Scales (DASS), or Montgomery-Asberg Depression Rating Scale (MADRS) were included.Results: 12 RCTs involving 707 participants were included. Seven RCTs utilizing the BDI questionnaire demonstrated a significant decrease in depressive symptoms favoring probiotics containing strains such as Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus salivarius, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium breve, and Bifidobacterium longum (MD: -2.69, CI95%: -4.22/-1.16, p value: 0.00). Conversely, RCTs using HAMD showed a non-significant reduction in depressive symptoms (MD: -1.40, CI95%: -3.29/0.48, p value: 0.14). RCTs employing DASS and MADRS scales also showed no significant differences.Conclusion: This meta-analysis offers valuable insights into the strain-specific effects of probiotics containing Lactobacillus and Bifidobacterium species on depressive and anxiety symptoms. While our findings suggest a significant reduction in depressive symptoms based on the BDI scale favoring probiotics, the lack of significant effects observed on the HAMD, DASS, and MADRS scales underscores the complexity inherent in these conditions. It is imperative to acknowledge the mixed results across different measurement scales, indicating the need for cautious interpretation. Therefore, we advocate for a nuanced understanding of probiotics' impacts on various dimensions of mood, emphasizing the necessity for further research.","PeriodicalId":12833,"journal":{"name":"Gut Pathogens","volume":"16 1","pages":"46"},"PeriodicalIF":4.3000,"publicationDate":"2024-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11382490/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut Pathogens","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13099-024-00634-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Depression and anxiety are pervasive mental health disorders with substantial global burdens. Probiotics, live microorganisms known for their health benefits, have emerged as a potential therapeutic intervention for these conditions. This systematic review and meta-analysis aim to evaluate the strain-specific effects of probiotics on relieving depressive and anxiety symptoms while elucidating underlying mechanisms.

Methods: EMBASE, Cochrane CENTRAL and PubMed/Medline were systematically queried to identify studies released until May 15, 2024. Randomized Controlled Trials (RCTs) that employed standardized assessment tools for depression and anxiety namely Beck Depression Inventory (BDI), Hamilton Depression Rating Scale (HAMD), Depression Anxiety Stress Scales (DASS), or Montgomery-Asberg Depression Rating Scale (MADRS) were included.

Results: 12 RCTs involving 707 participants were included. Seven RCTs utilizing the BDI questionnaire demonstrated a significant decrease in depressive symptoms favoring probiotics containing strains such as Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus casei, Lactobacillus plantarum, Lactobacillus salivarius, Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium breve, and Bifidobacterium longum (MD: -2.69, CI95%: -4.22/-1.16, p value: 0.00). Conversely, RCTs using HAMD showed a non-significant reduction in depressive symptoms (MD: -1.40, CI95%: -3.29/0.48, p value: 0.14). RCTs employing DASS and MADRS scales also showed no significant differences.

Conclusion: This meta-analysis offers valuable insights into the strain-specific effects of probiotics containing Lactobacillus and Bifidobacterium species on depressive and anxiety symptoms. While our findings suggest a significant reduction in depressive symptoms based on the BDI scale favoring probiotics, the lack of significant effects observed on the HAMD, DASS, and MADRS scales underscores the complexity inherent in these conditions. It is imperative to acknowledge the mixed results across different measurement scales, indicating the need for cautious interpretation. Therefore, we advocate for a nuanced understanding of probiotics' impacts on various dimensions of mood, emphasizing the necessity for further research.

查看原文本刊更多论文

益生菌菌株对抑郁和焦虑的特异性影响：一项荟萃分析。

引言抑郁症和焦虑症是普遍存在的精神疾病，给全球带来沉重负担。益生菌是一种以有益健康而闻名的活微生物，已成为治疗这些疾病的潜在干预措施。本系统综述和荟萃分析旨在评估益生菌对缓解抑郁和焦虑症状的特定菌株效应，同时阐明其潜在机制：系统查询了 EMBASE、Cochrane CENTRAL 和 PubMed/Medline，以确定 2024 年 5 月 15 日前发布的研究。纳入了采用标准化抑郁和焦虑评估工具（即贝克抑郁量表（BDI）、汉密尔顿抑郁评定量表（HAMD）、抑郁焦虑压力量表（DASS）或蒙哥马利-阿斯伯格抑郁评定量表（MADRS））的随机对照试验（RCT）：结果：共纳入了 12 项 RCT，涉及 707 名参与者。结果：共纳入 12 项研究，涉及 707 名参与者。7 项采用 BDI 问卷的研究表明，含有嗜酸乳杆菌、副酸乳杆菌、干酪乳杆菌、植物乳杆菌、唾液乳杆菌、双歧杆菌、乳双歧杆菌、乳酸双歧杆菌和长双歧杆菌等菌株的益生菌可显著减少抑郁症状（MD：-2.69，CI95%：-4.22/-1.16，P 值：0.00）。相反，使用 HAMD 的研究表明，抑郁症状的减少并不显著（MD：-1.40，CI95%：-3.29/0.48，P 值：0.14）。采用 DASS 和 MADRS 量表的 RCT 研究也未显示出显著差异：这项荟萃分析就含有乳酸杆菌和双歧杆菌的益生菌对抑郁和焦虑症状的菌株特异性影响提供了有价值的见解。虽然我们的研究结果表明，根据 BDI 量表，益生菌能显著减轻抑郁症状，但在 HAMD、DASS 和 MADRS 量表上观察到的效果并不明显，这凸显了这些症状固有的复杂性。必须承认，不同测量量表的结果参差不齐，这表明需要谨慎解释。因此，我们主张细致入微地了解益生菌对情绪各方面的影响，强调进一步研究的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gut Pathogens GASTROENTEROLOGY & HEPATOLOGY-MICROBIOLOGY

CiteScore

7.70

自引率

2.40%

发文量

期刊介绍： Gut Pathogens is a fast publishing, inclusive and prominent international journal which recognizes the need for a publishing platform uniquely tailored to reflect the full breadth of research in the biology and medicine of pathogens, commensals and functional microbiota of the gut. The journal publishes basic, clinical and cutting-edge research on all aspects of the above mentioned organisms including probiotic bacteria and yeasts and their products. The scope also covers the related ecology, molecular genetics, physiology and epidemiology of these microbes. The journal actively invites timely reports on the novel aspects of genomics, metagenomics, microbiota profiling and systems biology. Gut Pathogens will also consider, at the discretion of the editors, descriptive studies identifying a new genome sequence of a gut microbe or a series of related microbes (such as those obtained from new hosts, niches, settings, outbreaks and epidemics) and those obtained from single or multiple hosts at one or different time points (chronological evolution).